Stockscreener 앱 받기
0.517
0.08%
0.0004
시장 영업 전:
.50
-0.017
-3.29%
AIM ImmunoTech Inc 주식(AIM)의 최신 뉴스
AIM ImmunoTech (AIM) price target decreased by 54.50% to 10.20 - MSN
AIM Stock Price, Quote & Chart | AIM IMMUNOTECH INC (NYSEARCA:AIM) - ChartMill
AIM ImmunoTech Inc. Common Stock (NY: AIM - FinancialContent
AIM ImmunoTech Inc. (AIM) posts wider than expected Q4 2025 loss, yet shares rise modestly in today’s trading.Most Watched Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director - The National Law Review
AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP - ADVFN
AIM ImmunoTech advances Phase 3 planning for pancreatic cancer By Investing.com - Investing.com Australia
AIM ImmunoTech (AIM) Advances Pancreatic Cancer Treatment Plans - GuruFocus
AIM ImmunoTech IncExpects Next Duripanc St - Moomoo
AIM ImmunoTech Starts Late-Stage Trial of Ampligen in Pancreatic Cancer - Moomoo
AIM ImmunoTech advances Phase 3 planning for pancreatic cancer - Investing.com
AIM ImmunoTech Enters Pivotal Value Inflection Phase with - GlobeNewswire
AIM ImmunoTech Inc. announces that its core drug Ampligen® has reached a critical value inflection point in the field of pancreatic cancer treatment. - Bitget
AIM ImmunoTech Provides Routine Update on Annual Filings - ChartMill
AIM ImmunoTech Inc. Reports Audit Findings with Going Concern Emphasis and Positive Clinical Trial Progress for Ampligen in Pancreatic Cancer Treatment - Quiver Quantitative
Aim Immunotech Provides Routine Update On Annual Filings - TradingView
AIM ImmunoTech Inc. 8-K Filing Details Equity Distribution Agreement Amendment and NYSE American Listing - Minichart
AIM ImmunoTech Expands At-The-Market Equity Offering Capacity - TipRanks
AIM ImmunoTech's ATM Expansion Hides Ongoing Liquidity Stress and Shareholder Squeeze Risk - Bitget
AIM ImmunoTech amends equity distribution agreement to remove share sale limit - Investing.com Australia
AIM ImmunoTech Expands ATM Equity Program With Maxim, Removing Prior $3 Million Cap - TradingView
AIM ImmunoTech (NYSE: AIM) lifts cap on at-the-market stock sales - Stock Titan
AIM ImmunoTech (NYSE American: AIM) ups ATM capacity to $3.41M under S‑3 - Stock Titan
Constellation Brands To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
AIM Stock Target Price Lowered by Ascendiant Capital | AIM Stock News - GuruFocus
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event - marketscreener.com
AIM ImmunoTech CEO to take live investor questions on April 16 - Stock Titan
AIM SEC FilingsAim Immunotech 10-K, 10-Q, 8-K Forms - Stock Titan
AIM ImmunoTech Inc (AIM) Stock Price, Trades & News - GuruFocus
AIM Stock Analysis: AIM ImmunoTech Inc. hits 0.59 on 8.18 percent biotech rally - Xã Thanh Hà
AIM ImmunoTech Inc. (AIM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is AIM ImmunoTech (AIM) stock outpacing its medical peers this year? - MSN
AIM PE Ratio & Valuation, Is AIM Overvalued - Intellectia AI
AIM Stock Analysis: AIM ImmunoTech Inc. biotech performance update at 0.59 after minor daily advance - Cổng thông tin điện tử Tỉnh Sơn La
AIM ImmunoTech 2025 Annual Report: Focus on Ampligen for Pancreatic Cancer, Clinical Trials, and R&D Highlights - Minichart
AIM ImmunoTech 10-K: $0.09M Revenue, $(8.62) EPS, $13.96M Net Loss - TradingView — Track All Markets
AIM ImmunoTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Going concern risk and oncology plans at AIM ImmunoTech (AIM) detailed - Stock Titan
What's going on with AIM ImmunoTech stock Friday? - msn.com
AIM ImmunoTech Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Earnings Scheduled For March 24, 2026 - Sahm
Thermo Fisher Scientific (TMO) Partners With AIM ImmunoTech on Phase 3 Cancer Trial - Insider Monkey
If You Invested $1,000 in Aim Immunotech (AIM) - Stock Titan
0.14%
0.48%
자본화:
|
볼륨(24시간):